Abstract:Introduction: Growing evidence suggests a link between right ventricular (RV) fibrosis, poor function of the pressure-overloaded RV, and mortality in pulmonary arterial hypertension (PAH). However, there are no currently available therapies that specifically target RV fibrosis. Using RV tissues from a preclinical rat PAH model, we previously reported that activation of stress-responsive protein kinase D (PKD) and phosphorylation of its substrate dynamin-related protein 1 (DRP1) occur specifically at the outer mitochondrial membrane (OMM) of RV cardiac fibroblasts (RV-CFs), but not in RV myocytes. RV-CFs isolated from PAH rats exhibited increased mitochondrial fission, mitochondrial reactive oxygen species (mROS), and proliferative signaling compared to RV-CFs from control animals, suggesting an association between PKD signaling in RV-CFs and RV fibrosis. Hypothesis: Inhibition of mitochondrial PKD signaling in CFs can attenuate RV fibrosis in PAH. Methods: Primary adult CFs from human ventricles were used for in vitro assays. A preclinical rat PAH model (Sugen 5416 injection and 3-week hypoxia followed by 4-week normoxia) was used for in vivo assays. Results: To specifically inhibit PKD activity at the OMM, an OMM-targeted dominant-negative PKD1 (mt-PKD-DN) was generated by adding an OMM-target sequence (amino acid 1-33 from human TOM20) at the N-terminus of PKD1-K612W. We confirmed that mt-PKD-DN is specifically expressed in mitochondria and decreases basal PKD activity only in mitochondria, assessed by protein fractionation. Importantly, mt-PKD-DN was able to inhibit mitochondrial fission, reduce mROS, hyperpolarize mitochondrial membrane potential, and ultimately decrease CF proliferation in vitro. To inhibit mitochondrial PKD activity in quiescent and resident CFs in vivo, we next administrated CF-selective adeno-associated virus serotype 9 (AAV9) carrying human TCF21 (hTCF21) promoter and mt-PKD-DN into the rat PAH model by tail vein injection. Introduction of AAV9-hTCF21-mt-PKD-DN or its control virus did not significantly alter baseline cardiac function. CF-specific mt-PKD-DN expression was able to significantly reduce RV hypertrophy/fibrosis, and RV-CF hyperproliferation as assessed by immunostaining of a nucleus-localized marker of active cell proliferation Ki67. Lastly, we found the partial recovery of in vivo RV function (i.e., recovery of tricuspid annular plane systolic excursion in echocardiography) in PAH rats with mt-PKD-DN. Conclusion: Targeting mitochondrial PKD may be a potential therapeutic strategy to reduce cardiac fibrosis under pathological conditions including PAH. R01HL136757 (to J.O.-U), AHA 18CDA34110091 (to B.S.J) This is the full abstract presented at the American Physiology Summit 2023 meeting and is only available in HTML format. There are no additional versions or additional content available for this abstract. Physiology was not involved in the peer review process.

Acetazolamide Improves Right Ventricular Function and Metabolic Gene Dysregulation in Experimental Pulmonary Arterial Hypertension

Fatty acid metabolism in pulmonary arterial hypertension: role in right ventricular dysfunction and hypertrophy

Comparative analysis of right ventricular metabolic reprogramming in pre-clinical rat models of severe pulmonary hypertension-induced right ventricular failure

Therapeutic inhibition of fatty acid oxidation in right ventricular hypertrophy: exploiting Randle's cycle

Abstract 4143932: Exploring P300/CBP as therapeutic approach for right ventricular dysfunction in PAH

Vanillic Acid Alleviates Right Ventricular Function in Rats With MCT-Induced Pulmonary Arterial Hypertension

Ppar Gamma Alleviates Right Ventricular Failure Secondary To Pulmonary Arterial Hypertension In Rats

Proteomic and Phosphoproteomic Analysis of Right Ventricular Hypertrophy in the Pulmonary Hypertension Rat Model

Ursolic Acid Improves Monocrotaline-Induced Right Ventricular Remodeling by Regulating Metabolism

Metabolic Reprogramming of the Right Ventricle and Pulmonary Arteries in a Flow-Associated Pulmonary Arterial Hypertension Rat Model

Selective inhibition of Histone deacetylases reverses vascular remodeling and improves right ventricle function in pulmonary hypertension

Transpulmonary amino acid metabolism in the sugen hypoxia model of pulmonary hypertension

Evaluation and Treatment of Endoplasmic Reticulum (ER) Stress in Right Ventricular Dysfunction during Monocrotaline-Induced Rat Pulmonary Arterial Hypertension

Glyoxylase-1 combats dicarbonyl stress and right ventricular dysfunction in rodent pulmonary arterial hypertension

Reversal of Right Ventricular Hypertrophy and Dysfunction by Prostacyclin in a Rat Model of Severe Pulmonary Arterial Hypertension

Abstract 15564: Transcriptional Profiling Unveils New Molecular Subgroups of Adaptive and Maladaptive Right Ventricular Remodeling in Pulmonary Hypertension

Proteomic Signatures of Right Ventricular Outcomes in Pulmonary Arterial Hypertension

Contribution of Impaired Parasympathetic Activity to Right Ventricular Dysfunction and Pulmonary Vascular Remodeling in Pulmonary Arterial Hypertension.

Role of mitochondrial PKD on right ventricular fibrosis under pulmonary hypertension

Antioxidant-Conjugated Peptide Attenuated Metabolic Reprogramming in Pulmonary Hypertension

Metabolic Reprogramming in the Heart and Lung in a Murine Model of Pulmonary Arterial Hypertension